Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022
Carr W, Kurbatova E, Starks A, Goswami N, Allen L, Winston C
MMWR. Morbidity and mortality weekly report · 2022-02
Abstract
On May 5, 2021, CDC's Tuberculosis Trials Consortium and the National Institutes of Health (NIH)-sponsored AIDS Clinical Trials Group (ACTG) published results from a randomized controlled trial indicating that a 4-month regimen containing rifapentine (RPT), moxifloxacin (MOX), isoniazid (INH), and pyrazinamide (PZA) was as effective as the standard 6-month regimen for tuberculosis (TB) treatment (1). On the basis of these findings, CDC recommends the 4-month regimen as a treatment option for U.S. patients aged ≥12 years with drug-susceptible pulmonary TB and provides implementation considerations for this treatment regimen.
MeSH terms
- Humans
- Tuberculosis, Pulmonary
- Isoniazid
- Pyrazinamide
- Rifampin
- Antitubercular Agents
- Drug Therapy, Combination
- Drug Administration Schedule
- United States
- Randomized Controlled Trials as Topic
- Moxifloxacin
- Centers for Disease Control and Prevention, U.S.